Wellgistics Health

WGRX

Market cap $105M

Wellgistics Health Inc (NASDAQ: WGRX) more than tripled this morning after announcing a non-binding letter of intent with Datavault AI Inc. (NASDAQ: DVLT). The initiative dubbed “PharmacyChain” will integrate blockchain-enabled smart contracts into its prescription drug tracking system.

Strategic Alliance Targets Digital Transformation of the $634.32 Billion (1) US Prescription Drug Market Through Blockchain-Enabled Data Monetization and AI-Driven Efficiency Gains

TAMPA, FLORIDA / ACCESS Newswire / October 13, 2025 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the re-appointment of Prashant Patel, RPh as President, Interim-CEO and Member of the Board of Directors. Mr. Patel had resigned from the positions of President & Member of the Board of Directors in August 2025.

TAMPA, FL / ACCESS Newswire / September 30, 2025 / Wellgistics Health, Inc. ("Wellgistics Health" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, the manufacturer of Brenzavvy® (bexagliflozin), to make diabetes medications more affordable and accessible across the U.S. healthcare system. The joint effort leverages Wellgistics Health's "maker-to-taker" platform - a direct pipeline that connects manufacturers to pharmacies and patients while bypassing costly intermediaries.

TAMPA, FL / ACCESS Newswire / September 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the pricing of a public offering of 7,142,862 shares of common stock, together with warrants to purchase up to 7,142,862 shares of common stock at a combined public offering price of $0.70 per share and associated warrant. The warrants will have an exercise price of $0.70 per share, will be exercisable upon issuance and will expire five years thereafter.

In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience. TAMPA, FL / ACCESS Newswire / September 24, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the launch of a new capital access program in collaboration with RxERP Financial.

TAMPA, FL / ACCESS Newswire / September 5, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that Brian Norton, Chief Executive Officer, together with members of the Company's executive leadership team, will present at three upcoming investor conferences in September 2025 as follows: EVENT: H.​C. Wainwright 27th Annual Global Investment Conference DATE: Monday, September 8, 2025TIME: 1:30 p.m.

TAMPA, FL / ACCESS Newswire / August 27, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the introduction of HubRx AI - a fully customizable AI engine built to streamline prescription hub services, reduce costs, and improve patient outcomes. What HubRx AI Delivers HubRx AI is an in-house, full-stack AI agent engine that integrates with Wellgistics Health's platform.

TAMPA, FLORIDA / ACCESS Newswire / August 20, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced financial results for the second fiscal quarter ended June 30, 2025. Financial Results Revenue on a pro forma basis, which reflects results as if Wellgistics' distribution operations had been part of the Company for the full comparable periods, was $18.65 million in the first half of 2025 compared to $18.25 million in the first half of 2024.

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC. The ELOC was an effective tool that nearly doubled the Company's original IPO raise.